Navigation Links
Clinical Trials of New Drug Febuxostat Show Promise in Gout Treatment

A new drug called febuxostat has been found to reduce plasma levels of uric acid more effectively in Gout than the currently used drug allopurinol. If the results of the clinical trial are successful//, then it would mean the end of a 40 year search for successful treatment of Gout.

Gout is characterized by accumulation and deposition of needle shaped uric acid crystals in the joints, thereby leading to inflammation and pain. Progressively, it leads to a condition called ‘Gouty arthritis’ and is associated by a significant reduction in joint mobility.

The only existing standard treatment for Gout is administration of allopurinol, which reduces the levels of uric acid production by blocking certain key steps in uric acid synthesis. In addition, it also decreases the plasma levels of uric acid over a period of time.

The study was conducted amongst a group of 762 patients, diagnosed to suffer from Gout and is believed to be the largest clinical trial ever done on patients with Gout. The mechanism of action of Febuxostat is very similar to allopurinol.

The study participants were either given allopurinol or febuxostat (two different doses) as a form of treatment, the goal of which was to reduce plasma uric acid levels by as much as 6 mg/dl. Allopurinol treatment was taken by 21% of the members, followed by 53 and 62% who took 80 and 120mg of febuxostat respectively.

At the end of the study, it was found that the new drug was more effective than allopurinol when used for more than a year, as revealed by statistical tests. However, a large number of patients were found to discontinue from the study due to the high incidence of adverse effects. The main site of drug metabolism is the liver which facilitates administration of the drug to patients with compromised kidney function as well.

The drug has not yet been approved by the U.S. Food and Drug Administration agency (FDA) for therapeutic use. More studies are clearly indicated to determine the long term clinical benefits of the new drug, taking into critical consideration the safety.
'"/>




Related medicine news :

1. Clinical trials need to be more frank
2. Physicians Lack Clinical Guidelines For Treating Elderly With Multiple Illnesses
3. The Growing Rise In Clinical Research Could Lead To A Compromise In Quality Of Research And Ethics
4. Clinical Comparisons Between ADHD Drugs Are Less
5. A Novel System For Clinical Banking Of Umbilical Cord Blood
6. Clinical Renal Trails Do Not Have Sufficient Women Participants
7. Clinical Trials Of New Anti-Cancer Drug To Be Initiated In New Zealand
8. Green Tea Consumption Found To Improve Clinical Outcome In Cancer Patients
9. Cancer Clinical Research in India
10. New Generation Clinical Trials Could Save Time And Money, Improve Patient Care
11. Clinical Impact of Activity and Abdominal Pressure on Pelvic Floor Dysfunction Need to Be Further Analyzed
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills ... specialty vendors and unique items from across the nation, this holiday-themed event will raise ... offered by the VNA. The boutique will be open Saturday, November 4 (10:00 ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), an ... showcase a range of technology and learning solutions at the 68th Annual American ... to be held October 14–18, 2017 at the Mandalay Bay Resort in Las ...
(Date:10/12/2017)... PALM CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... of cold therapy products, announced today the introduction of an innovative new design of ... the multipurpose pad so you get maximum comfort while controlling your pain while using ...
(Date:10/12/2017)... ... 12, 2017 , ... Dr. Parsa Mohebi, the Los Angeles ... to the newly revamped Cosmetic Town journal section, featuring articles written ... known as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... LAWRENCE, Mass. , Oct. 4, 2017 /PRNewswire/ ... developer of single-use, self-contained, illuminating medical devices, today ... National Health Surveillance Agency (or Agência Nacional ... ®. The first single-use, cordless surgical retractor with ... ONETRAC provides optimal access, illumination and exposure of ...
(Date:10/2/2017)... The Rebound mobile app is poised to become a vital ... prescription drug addiction. The app empowers users to develop an ... their dosage in a safe, controlled manner while maximizing well-being. ... 100,000 people to sign up will enjoy 3 months of ... ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
Breaking Medicine Technology: